Market Closed -
Nasdaq
16:00:00 2024-05-15 EDT
5-day change
1st Jan Change
13.34
USD
+0.76%
+4.55%
+41.76%
This article is reserved for members
Not a member ?
Free registration
JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating
05-07
MT
Transcript : Enanta Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 06, 2024
05-06
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, vs. Street Est of $16.2M
05-06
MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
05-06
CI
Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer
04-30
CI
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating
02-09
MT
Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024
02-07
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $18M, vs. Street Est of $21.9M
02-07
MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
02-07
CI
Transcript : Enanta Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM
01-10
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024
12-26
CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from NASDAQ Biotechnology Index
12-15
CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
11-24
MT
Sector Update: Health Care
11-24
MT
Enanta Pharmaceuticals Files $150 Million Mixed Shelf
11-24
MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating
11-22
MT
HC Wainwright Cuts Enanta Pharmaceuticals' Price Target to $28 From $30, Maintains Buy Rating
11-21
MT
Transcript : Enanta Pharmaceuticals, Inc., Q4 2023 Earnings Call, Nov 20, 2023
11-20
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q4 Revenue $18.9M, vs. Street Est of $17.5M
11-20
MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
11-20
CI
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023
11-20
CI
HC Wainwright Adjusts Enanta Pharmaceuticals Price Target to $30 From $48, Maintains Buy Rating
23-10-23
MT
Transcript : Enanta Pharmaceuticals, Inc. - Special Call
23-10-20
Enanta Pharmaceuticals Receives Speculative Risk Qualifier on Sector Perform Rating From RBC, Price Target Cut to $15 From $25
23-10-02
MT
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from S&P Biotechnology Select Industry Index
23-09-18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).
More about the company
Last Close Price
13.34
USD
Average target price
19.75
USD
Spread / Average Target
+48.05%
Consensus
1st Jan change
Capi.
+41.76% 283M +29.77% 49.46B +1.00% 42.58B +49.62% 42.49B -5.26% 29.09B +13.68% 26.61B -22.99% 18.64B +8.22% 13.16B +32.41% 12.55B +24.01% 12.1B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**